Abstract
The term “disease modifying drugs” (DMD) is taken from rheumatologists who coined it after the use of immunosuppressive drugs and, more recently, the association of “biological drugs” that changed the degenerative course of rheumatic disease.
In the treatment of multiple sclerosis (MS), the advent of interferon (IFN)-β, which caused a reduction in the number of relapses and possibly improvement in disability outcomes, was the first strategy to prevent inflammatory damage in the central nervous system (CNS). Soon after, glatiramer acetate showed similar results. It would be more than a decade before natalizumab was licensed, showing a much better efficiency in relapse reduction than was seen after first-line therapies failed. The pipeline is now much larger with several drugs on the horizon. Overall, the anti-inflammatory strategy has been mostly successful but drugs that have protection and repair mechanisms are still missing.
Keywords: Multiple sclerosis, treatments, mechanisms of action.
CNS & Neurological Disorders - Drug Targets
Title:Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon
Volume: 11 Issue: 5
Author(s): Monica Marta and Gavin Giovannoni
Affiliation:
Keywords: Multiple sclerosis, treatments, mechanisms of action.
Abstract: The term “disease modifying drugs” (DMD) is taken from rheumatologists who coined it after the use of immunosuppressive drugs and, more recently, the association of “biological drugs” that changed the degenerative course of rheumatic disease.
In the treatment of multiple sclerosis (MS), the advent of interferon (IFN)-β, which caused a reduction in the number of relapses and possibly improvement in disability outcomes, was the first strategy to prevent inflammatory damage in the central nervous system (CNS). Soon after, glatiramer acetate showed similar results. It would be more than a decade before natalizumab was licensed, showing a much better efficiency in relapse reduction than was seen after first-line therapies failed. The pipeline is now much larger with several drugs on the horizon. Overall, the anti-inflammatory strategy has been mostly successful but drugs that have protection and repair mechanisms are still missing.
Export Options
About this article
Cite this article as:
Marta Monica and Giovannoni Gavin, Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon, CNS & Neurological Disorders - Drug Targets 2012; 11 (5) . https://dx.doi.org/10.2174/187152712801661301
DOI https://dx.doi.org/10.2174/187152712801661301 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Is Human Immunodeficiency Virus-Mediated Dementia an Autophagic Defect that Leads to Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Neuroinflammation and Neuroprotection: An Update on (Future) Neurotrophin-Related Strategies in Multiple Sclerosis Treatment
Current Medicinal Chemistry Editorial [Hot Topic: Tropical Neurology (Guest Editor: Terezinha C.B. Montelli)]
Central Nervous System Agents in Medicinal Chemistry Novel Phospholipase-Resistant Lipid/Peptide Synthetic Lung Surfactants
Mini-Reviews in Medicinal Chemistry Characterization and antiherpetic activity of native and chemically sulfated polysaccharide from <i>Adenanthera pavonina</i>
Current Pharmaceutical Biotechnology Cerebral Amyloidoses: Molecular Pathways and Therapeutic Challenges
Current Medicinal Chemistry A Concise Review on Multidimensional Silver Nanoparticle Health Aids and Threats
Current Drug Therapy Glycyrrhizic Acid Derivatives as New Antiviral and Immune Modulating Agents
Current Bioactive Compounds Assessment of Gene Transfer Using Imaging Methodology
Current Genomics Drug Targets in Infections with Ebola and Marburg Viruses
Infectious Disorders - Drug Targets The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders I: Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Development of HIV Reservoir Targeted Long Acting Nanoformulated Antiretroviral Therapies
Current Medicinal Chemistry Assessing Activation States in Microglia
CNS & Neurological Disorders - Drug Targets Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Conditional Tat Protein Brain Expression in the GT-tg Bigenic Mouse Induces Cerebral Fractional Anisotropy Abnormalities
Current HIV Research Biological Activities of Artemisinin Derivatives Beyond Malaria
Current Topics in Medicinal Chemistry Recent Advances in the Discovery of Novel Anti-Herpetic Agents from Chinese Herbal Medicines
Current Organic Chemistry Heterocycles in the Treatment of Neglected Tropical Diseases
Current Medicinal Chemistry Immunological Mechanisms of Neuropsychiatric Lupus
Current Immunology Reviews (Discontinued) Novel Concepts for Anti-Infective Activity of Cytokines, Chemokines and Diverse Agents
Recent Patents on Anti-Infective Drug Discovery